Abstract
The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in an open label study in 37 frail institutionalized persons over age 65. Vaccination was well tolerated without significant side-effects. Thirty-six of 37 volunteers completed the study. Nineteen of 36 (53%) vaccinees had a greater than or equal to fourfold increase in IgG to F protein at 4 weeks and 17 (47%) had a greater than or equal to fourfold rise in neutralizing titers to either group A or B virus. Although response rate to PFP-2 vaccine in the frail elderly was somewhat diminished compared to results in the healthy elderly, the vaccine was well tolerated and relatively immunogenic.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antibodies, Viral / blood
-
Chronic Disease
-
Female
-
Homes for the Aged
-
Humans
-
Immunoglobulin G / blood
-
Male
-
Neutralization Tests
-
Nursing Homes
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus, Human / immunology*
-
Respiratory Tract Infections / immunology
-
Respiratory Tract Infections / prevention & control*
-
Safety
-
Vaccines, Synthetic / pharmacology*
-
Viral Fusion Proteins / immunology
-
Viral Vaccines / adverse effects
-
Viral Vaccines / pharmacology*
Substances
-
Antibodies, Viral
-
Immunoglobulin G
-
Vaccines, Synthetic
-
Viral Fusion Proteins
-
Viral Vaccines